Akèy › Kansè Ipofaringe
Etid klinik pou Kansè Ipofaringe ap rekrite nan Etazini
19 etid pou Kansè Ipofaringe ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Atlanta, GA6 etid
- Chicago, IL6 etid
- Stevens Point, WI5 etid
- Joliet, IL5 etid
- Peoria, IL5 etid
- Bloomington, IL5 etid
- Wausau, WI5 etid
- Richmond, VA5 etid
- Cape Girardeau, MO5 etid
- Milwaukee, WI5 etid
- Kansas City, MO5 etid
- New York City, NY4 etid
- Edison, NJ4 etid
- Queens, NY4 etid
- Waukegan, IL4 etid
- Green Bay, WI4 etid
- Cedar Rapids, IA4 etid
- Evanston, IL4 etid
- Danville, IL4 etid
- Fargo, ND4 etid
- Lansing, MI4 etid
- Omaha, NE4 etid
- Champaign, IL4 etid
- Decatur, IL4 etid
- Aurora, IL4 etid
- St. Louis, MO4 etid
- Galesburg, IL4 etid
- Naperville, IL4 etid
- Flint, MI4 etid
- Oklahoma City, OK4 etid
- Charleston, IL4 etid
- Cicero, IL4 etid
- North Peoria, IL4 etid
- Waterford, MI4 etid
- Bozeman, MT4 etid
- Duluth, MN4 etid
- Pittsburgh, PA4 etid
- Baltimore, MD4 etid
- Cincinnati, OH4 etid
- Louisville, KY4 etid
Pa eta
- Arizona3 etid
- Arkansas4 etid
- Colorado6 etid
- Florid8 etid
- Georgia6 etid
- Idaho3 etid
- Illinois7 etid
- Indiana4 etid
- Iowa6 etid
- Kalifòni7 etid
- Kansas6 etid
- Kentucky4 etid
- Maryland5 etid
- Massachusetts5 etid
- Michigan5 etid
- Minnesota6 etid
- Missouri6 etid
- Montana4 etid
- Nebraska4 etid
- New Jersey4 etid
- New York8 etid
- North Carolina5 etid
- North Dakota4 etid
- Ohio8 etid
- Oklahoma4 etid
- Oregon3 etid
- Pennsylvania6 etid
- South Dakota3 etid
- Texas3 etid
- Virginia5 etid
- Wisconsin6 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06589804Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06997068BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05136196Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT05172245Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT02734537Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07156227Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT06532279Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT07441681Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT04198766Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 16, 2026 · NCT06662058Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 15, 2026 · NCT01365169Integrated Cancer Repository for Cancer Research
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2026 · NCT03010150TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 4, 2026 · NCT06868433A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 19, 2026 · NCT07063212Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 11, 2026 · NCT06636734Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Feb 10, 2026 · NCT01473784Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Oct 22, 2025 · NCT06914999Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
Ap rekriteEtid obsèvasyon
Laj 21 a 90 · Tout sèks · Mizajou Sep 22, 2025 · NCT00900419Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.